Infusion of regulatory T cells (Tregs) engineered with a chimeric antigen receptor (CAR)
targeting donor-derived human leukocyte antigen (HLA) is a promising strategy to promote …

Adoptive immunotherapy with regulatory T cells (Tregs) is a promising treatment for allograft
rejection and graft-versus-host disease (GVHD). Emerging data indicate that, compared with …

Chimeric antigen receptor (CAR) technology can be used to engineer the antigen specificity
of regulatory T cells (Tregs) and improve their potency as an adoptive cell therapy in multiple …

Solid organ transplantation is the treatment of choice for various end-stage diseases, but
requires the continuous need for immunosuppression to prevent allograft rejection. This …

Alloantigen-specific regulatory T cell (Treg) therapy is a promising approach for suppressing
alloimmune responses and minimizing immunosuppression after solid organ …

Regulatory T cell (Treg) therapy using recipient-derived Tregs expanded ex vivo is currently
being investigated clinically by us and others as a means of reducing allograft rejection …

A primary goal in transplantation medicine is the induction of a tolerogenic environment for
prevention of transplant rejection without the need for long-term pharmacological …

Cellular therapies based on permanent genetic modification of conventional T cells have
emerged as a promising strategy for cancer. However, it remains unknown if modification of …

Cell therapy with autologous donor-specific regulatory T cells (Tregs) is a promising strategy
to minimize immunosuppression in transplant recipients. Chimeric antigen receptor (CAR) …

Adoptive transfer of Ag-specific T lymphocytes is an attractive form of immunotherapy for
cancers. However, acquiring sufficient numbers of host-derived tumor-specific T …